THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES
https://doi.org/10.20996/1819-6446-2016-12-2-186-190
Abstract
The interdisciplinary interim experts’ council on March 3, 2016 in Moscow have considered the EMPA-REG OUTCOME trial results and suggested a number of propositions and recommendations on further empagliflozin’s cardiovascular effects investigation and its clinical application in patients with type 2 diabetes at high cardiovascular risk.
About the Authors
M. V. Shestakova
Institute of Diabetes, Endocrinology Research Center, Moscow
Russian Federation
Russian Federation
S. A. Boytsov
State Research Centre for Preventive Medicine, Moscow
Russian Federation
Russian Federation
O. M. Drapkina
State Research Centre for Preventive Medicine, Moscow
Russian Federation
Russian Federation
T. Yu. Demidova
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
H. Drexel
Vorarlberg Institute for Vascular Investigation and Treatment,Feldkirch
Austria
Austria
M. B. Antsiferov
Endocrinology Clinic of Moscow, Moscow
Russian Federation
Russian Federation
N. A. Petunina
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
N. A. Chernikova
Russian Medical Academy of Postgraduate Education, Moscow
Russian Federation
Russian Federation
V. Yu. Kalashnikov
Institute of Diabetes, Endocrinology Research Center, Moscow
Russian Federation
Russian Federation
T. P. Bardymova
Irkutsk State Medical Academy of Postgraduate Education, Irkutsk
Russian Federation
Russian Federation
V. K. Protasov
Irkutsk State Medical Academy of Postgraduate Education, Irkutsk
Russian Federation
Russian Federation
A. Yu. Babenko
Institute of Endocrinology, V.A. Almazov Northwestern Federal Medical Research Center, St. Petersburg
Russian Federation
Russian Federation
L. A. Ruyatkina
Novosibirsk State Medical University, Novosibirsk
Russian Federation
Russian Federation
V. V. Klimontov
Novosibirsk State Medical University, Novosibirsk
Russian Federation
Russian Federation
V. V. Salukhov
S.M. Kirov Military Medical Academy, St. Petersburg
Russian Federation
Russian Federation
V. V. Fadeev
Institute of Diabetes, Endocrinology Research Center, Moscow; I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation
Russian Federation
Yu. A. Karpov
A.L. Myasnikov Institute of Clinical Cardiology, Russian Cardiology Research and Production Complex, Moscow
Russian Federation
Russian Federation
References
1. Zinman B, Wanner C, Lachin JM, et al., EMPA REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
2. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type
3. diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial. Eur Heart J. 2016 Jan 26. [Epub ahead of print]
Review
For citations:
Shestakova M.V., Boytsov S.A., Drapkina O.M., Demidova T.Yu., Drexel H., Antsiferov M.B., Petunina N.A., Chernikova N.A., Kalashnikov V.Yu., Bardymova T.P., Protasov V.K., Babenko A.Yu., Ruyatkina L.A., Klimontov V.V., Salukhov V.V., Fadeev V.V., Karpov Yu.A. THE INTERIM EXPERTS’ COUNCIL RESOLUTION ON THE EMPA-REG OUTCOME TRIAL ISSUES. Rational Pharmacotherapy in Cardiology. 2016;12(2):186-190. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-2-186-190
Views: 708
Email this article 